Page 5 - Deals Andm Amp A News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deals andm amp a. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deals Andm Amp A Today - Breaking & Trending Today

Itch a wrap: Cymabay PBC story ends with $4.3B Gilead buy

Seeking to rejuvenate itself after recent disappointments, Gilead Sciences Inc. proposes to bolster its liver portfolio by taking over Cymabay Therapeutics Inc. for $32.50 per share in cash, a total equity value of $4.3 billion. The arrangement brings aboard seladelpar for second-line primary biliary cholangitis (PBC) including pruritis (itch), which is under priority review by the U.S. FDA, with a decision due this year. ....

Gilead Sciences Inc , Cymabay Therapeutics Inc , Gilead Sciences , Cymabay Therapeutics , Gilead Sciences Inc , Cymabay Therapeutics Inc , Primary Biliary Cholangitis , Deals Andm Amp A ,

Takeda and Protagonist ink global license and development deal worth $1.7B for hematology asset rusfertide

Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of polycythemia vera (PV), a rare and chronic blood disorder affecting bone marrow. ....

Protagonist Therapeutics Inc , Takeda Pharmaceutical Co , Takeda Pharmaceutical , Protagonist Therapeutics , Takeda Pharmaceutical Co Ltd , Protagonist Therapeutics Inc , Polycythemia Vera , Bone Marrow , Hepcidin Mimetic Peptide , Deals Andm Amp A , Asia Pacific , Bioworld Asia ,

Novartis paying €2.7B for longtime antibody player Morphosys

More than 30 years after entering the scene as a first-generation monoclonal antibody pioneer, Morphosys AG is to be acquired by Novartis AG for €2.7 billion (US$2.9 billion). The all-cash deal, announced after Nasdaq closed on Feb. 5, will see Novartis paying €68 per share, a premium of 94% to the average daily price in the month leading up to Jan. 25, when rumors of a takeover started swirling. ....

Morphosys Ag , Novartis Ag , Deals Andm Amp A , Incyte Pharma Inc , Bet Inhibitor , Anti Cd19 Antibody ,

Jazz gains Redx's KRAS inhibitors in $880M deal

Redx Pharma plc has closed its biggest transaction to date, selling a preclinical KRAS inhibitor program to Jazz Pharmaceuticals plc in a potential $880 million deal. Of that, $10 million will be paid up front, with the balance to come in development and commercialization milestones. For any product that makes it to market, Redx will in addition receive tiered mid-single digit percentage royalties. ....

Redx Pharma , Jazz Pharmaceuticals , Redx Pharma Plc , Jazz Pharmaceuticals Plc , Kras Inhibitors , Colorectal Cancer , Idiopathic Pulmonary Fibrosis , Pancreatic Cancer , Non Small Cell Lung Cancer , Deals Andm Amp A ,

Takeda and Protagonist ink global license and development deal worth $1.7B for hematology asset rusfertide

Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of polycythemia vera (PV), a rare and chronic blood disorder affecting bone marrow. ....

Takeda Pharmaceutical Co , Protagonist Therapeutics Inc , Takeda Pharmaceutical , Protagonist Therapeutics , Takeda Pharmaceutical Co Ltd , Protagonist Therapeutics Inc , Polycythemia Vera , Bone Marrow , Hepcidin Mimetic Peptide , Deals Andm Amp A , Asia Pacific ,